Search

Search Results

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2047

  PDF: 1715

  HTML: 269

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1593

  PDF: 852

  HTML: 207

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1499

  PDF: 1280

  HTML: 327

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  2265

  PDF: 1753

  HTML: 945

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1231

  PDF: 985

  HTML: 202

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1741

  PDF: 1294

  HTML: 512

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1645

  PDF: 657

  HTML: 1053

• Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

  Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci

  e2024041

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.041

  1293

  PDF: 1083

  Suppl. Files: 723

  HTML: 84

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1080

  PDF: 644

  Html: 169

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1616

  PDF: 1416

  HTML: 143

• Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy

  Gianluca Cavallaro

  e2024049

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.049

  2265

  HTML: 149

  PDF: 1170

• Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

  Edoardo Olivari

  e2025040

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.040

  1091

  PDF: 796

  HTML: 196

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1517

  PDF: 396

  Html: 190

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5959

  PDF: 2385

  HTML: 1519

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1514

  PDF: 560

  HTML: 234

• Internal Medicine Ward with Hematological Skills for the Treatment of Complications Suffered by Hematological Patients on Therapy: Experience of Villa Betania Hospital inRome

  alessandro andriani, Laura Marchetti, Fabio Rossi, Silvia Raja, Maria Antonietta Perretti, Umberto Recine

  e2024030

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.030

  659

  PDF: 1060

  HTML: 99

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5338

  PDF: 1979

  HTML: 1788

• Multiple myeloma diagnosed by CT-guided rib biopsy after a hemodilute bone marrow aspirate, in a patient with a biclonal pattern on serum protein electrophoresis Multiple Myeloma diagnosed with CT-guided rib biopsy

  Arjeta Cyrbja, Liri Seraj, Shaqir Qerama

  e2026061

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.061

  209

  PDF: 97

  HTML: 118

• A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

  Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci

  e2023012

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.012

  1045

  PDF: 975

  HTML: 419

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  2111

  PDF: 873

  HTML: 354

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2244

  PDF: 1646

  HTML: 403

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  799

  PDF: 1176

  HTML: 94

• IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES

  Silvia Maria Trisolini, Alessandro Laganà, Saveria Capria

  e2024060

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.060

  2380

  PDF: 1911

  HTML: 172

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1323

  PDF: 1098

  HTML: 244

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2527

  HTML: 296

  PDF: 926

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7766

  PDF: 2463

  HTML: 2103

  Table 1.: 234

  Table 2.: 244

  Table 3.: 226

  Table 4.: 219

• IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma

  Hongfeng Wang, Jianbin Chen

  e2026062

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.062

  145

  PDF: 460

  HTML: 45

• NG2 MOLECULE EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA B CELLS: A FLOW-CYTOMETRIC MARKER FOR THE RAPID IDENTIFICATION OF KMT2A GENE REARRANGEMENTS

  Maria Laura Bisegna, Nadia Peragine, Loredana Elia, Mabel Matarazzo, Maria Laura Milani, Stefania Intoppa, Mariangela Di Trani, Francesco Malfona, Maurizio Martelli, Maria Stefania De Propris

  e2024018

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.018

  1024

  PDF: 1324

  Suppl. Files: 839

  HTML: 183

• The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients

  Hesham Elsabah, Mahmood B. Aldabt, Ruba Taha, Dina Sameh Soliman, Halima Elomri, Feryal Ibrahim

  e2020082

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.082

  1044

  PDF: 384

  HTML: 238

• MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

  Francesca Fazio, Gianfranco Lapietra, Maria Zaira Limongi, Stefania Intoppa, Maria Laura Milani, Alfonso Piciocchi, Maurizio Martelli, Anna Guarini, Robin Foà, Maria Stefania De Propris, Maria Teresa Petrucci

  e2023047

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.047

  1061

  PDF: 751

  HTML: 284

• Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the Coronavirus Disease 2019 (COVID-19) Pandemic: An Iranian Consensus

  Seied Asadollah Mousavi, Soroush Rad, Tahereh Rostami, Mohammad Vaezi, Hosein Kamranzadeh, Davood Babakhani, Sahar Tavakoli, Maryam Barkhordar, Tanaz Bahri, Amirabbas Hedayatiasl, azade kiumarsi

  e2020050

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.050

  1358

  PDF: 710

  HTML: 226

• Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma

  Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti

  e2025051

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.051

  783

  PDF: 605

  HTML: 48

• REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.

  Abdalla Awidi, Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa”neh, Feras Al-fararjeh

  e2022031

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.031

  1351

  PDF: 771

  HTML: 413